Q-omics provides the consensus-scored GAPDHP64 profile across patient tissues and cancer cell-line models. GAPDHP64 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, GAPDHP64 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GAPDHP64 RNA expression shows 6,116 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight LUSC, KIRC, and UCEC as cancer lineages where GAPDHP64 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP64 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP64 survival associations across molecular data types. GAPDHP64 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP64 RNA expression–survival associations across cancer types. High GAPDHP64 expression shows unfavorable associations in KICH, MESO, LUAD, BLCA and COAD, but favorable associations in LUSC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for GAPDHP64 RNA expression.
This table summarizes GAPDHP64 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP64. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP64 shows higher tumor expression in KIRC, LIHC, LUSC, HNSC, COAD and BRCA. The KIRC box plot shows higher GAPDHP64 RNA expression in tumor versus normal tissue (log2 FC = +0.150, t-test p < 0.001).
This table shows molecular features associated with GAPDHP64 in patient tissues and cancer cell lines. In patient samples, GAPDHP64 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
